Unnamed: 0,title,date,stock,sentiment
1406512.0,"Larimar Therapeutics (Formerly Zafgen) 8-K Shows Securities Purchase Deal For Private Placement Of 6.105M Shares, Pre-Funded Warrants For ~628K Shares At $11.8/Share, Warrant",2020-06-02 07:58:00-04:00,ZFGN,positive
1406513.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,ZFGN,positive
1406514.0,"Zafgen Shares Volatile Over Last Few Mins, Make Parabolic Move, Following Circulation Of Report Deal With Larimar Therapeutics Was Approved",2020-05-28 15:13:00-04:00,ZFGN,positive
1406515.0,20 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-05-07 07:32:00-04:00,ZFGN,neutral
1406516.0,"The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company",2020-03-20 07:44:00-04:00,ZFGN,negative
1406517.0,Zafgen Q4 EPS $(0.19) Up From $(0.39) YoY,2020-03-05 16:10:00-05:00,ZFGN,neutral
1406518.0,Renaissance Technologies Reports 6.38% Passive Stake In Zafgen,2020-02-12 11:59:00-05:00,ZFGN,positive
1406519.0,Sphera Funds Management Repprts 7.59% Passive Stake In Zafgen,2020-02-11 12:25:00-05:00,ZFGN,positive
1406520.0,98 Biotechnology Stocks Moving In Wednesday's Session,2020-01-22 13:33:00-05:00,ZFGN,neutral
1406521.0,116 Healthcare Stocks Moving In Wednesday's Session,2020-01-22 12:37:00-05:00,ZFGN,neutral
1406522.0,Chondrial Therapeutics Reports 14.4% Active Stake In Zafgen,2019-12-30 09:31:00-05:00,ZFGN,positive
1406523.0,36 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-12-19 08:28:00-05:00,ZFGN,neutral
1406524.0,"The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic",2019-12-19 07:52:00-05:00,ZFGN,negative
1406525.0,Stocks That Hit 52-Week Lows On Wednesday,2019-12-18 13:51:00-05:00,ZFGN,negative
1406526.0,30 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-12-18 08:11:00-05:00,ZFGN,neutral
1406527.0,Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement; Zafgen Shareholders to Own 40% of Combined Co,2019-12-18 06:02:00-05:00,ZFGN,positive
1406528.0,Zafgen And Chondrial Announce Merger Agreement Under Which Chondrial Will Become A Wholly-Owned Subsidiary Of Zafgen,2019-12-18 06:01:00-05:00,ZFGN,positive
1406529.0,Zafgen Q3 EPS $(0.35) Misses $(0.27) Estimate,2019-11-06 16:02:00-05:00,ZFGN,negative
1406530.0,Zafgen 13G Filing From EcoR1 Capital Shows 7% Stake,2019-10-15 17:17:00-04:00,ZFGN,neutral
1406531.0,"Zafgen Shares Resume Trade, Down 2.09%",2019-10-11 10:42:00-04:00,ZFGN,positive
1406532.0,Zafgen Commences Reduction In Workforce; Co. To Cut Employees By ~48%,2019-09-12 17:22:00-04:00,ZFGN,negative
1406533.0,27 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-09-09 08:42:00-04:00,ZFGN,neutral
1406534.0,"Benzinga's Top Upgrades, Downgrades For September 6, 2019",2019-09-06 09:37:00-04:00,ZFGN,positive
1406535.0,16 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-06 08:31:00-04:00,ZFGN,neutral
1406536.0,"The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication",2019-09-06 07:27:00-04:00,ZFGN,neutral
1406537.0,"Wedbush Downgrades Zafgen to Neutral, Lowers Price Target to $0.78",2019-09-06 07:16:00-04:00,ZFGN,negative
1406538.0,"Zafgen To Explore Strategic Options, With No Near-Term Resolution For Diabetes Drug",2019-09-05 11:24:00-04:00,ZFGN,negative
1406539.0,JMP Securities Downgrades Zafgen to Market Perform,2019-09-05 11:05:00-04:00,ZFGN,positive
1406540.0,"Zafgen Shares Resume Trade, Up 8%",2019-09-05 07:31:00-04:00,ZFGN,positive
1406541.0,Zafgen Shares To Resume Trade At 7:30 a.m. EDT,2019-09-05 07:07:00-04:00,ZFGN,positive
1406542.0,Zafgen To Explore Strategic Alternatives,2019-09-05 07:00:00-04:00,ZFGN,neutral
1406543.0,Zafgen Shares Halted News Pending,2019-09-05 06:55:00-04:00,ZFGN,positive
1406544.0,"The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved",2019-08-28 07:31:00-04:00,ZFGN,positive
1406545.0,"The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO",2019-08-27 07:29:00-04:00,ZFGN,positive
1406546.0,Zafgen Q2 EPS $(0.32) Beats $(0.36) Estimate,2019-08-08 16:44:00-04:00,ZFGN,neutral
1406547.0,Stocks That Broke Yearly Lows Tuesday Morning,2019-08-06 12:06:00-04:00,ZFGN,negative
1406548.0,40 Healthcare Stocks Moving In Thursday's After-Market Session,2019-08-02 04:10:00-04:00,ZFGN,neutral
1406549.0,New 52-Week Lows for Tuesday Morning,2019-07-30 11:07:00-04:00,ZFGN,negative
1406550.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,ZFGN,positive
1406551.0,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug",2019-07-25 07:21:00-04:00,ZFGN,negative
1406552.0,35 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-07-25 05:55:00-04:00,ZFGN,neutral
1406553.0,Zafgen Reports Deal FDA On New Nonclinical Study Design For ZGN-1061; Topline Data From In Vivo Study Expected By End Of 2019,2019-07-24 17:33:00-04:00,ZFGN,neutral
1406554.0,"The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index",2019-07-24 07:08:00-04:00,ZFGN,neutral
1406555.0,List of Companies Reaching Yearly Lows Tuesday,2019-07-23 14:58:00-04:00,ZFGN,neutral
1406556.0,"The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation",2019-07-23 07:26:00-04:00,ZFGN,negative
1406557.0,"The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO",2019-06-28 07:32:00-04:00,ZFGN,negative
1406558.0,Zafgen Highlights Full Results Of Phase 2 Trial For ZGN-1061 At American Diabetes Association's 79th Scientific Sessions,2019-06-10 07:21:00-04:00,ZFGN,neutral
1406559.0,"The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix",2019-06-07 07:24:00-04:00,ZFGN,positive
1406560.0,"The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering",2019-06-06 07:37:00-04:00,ZFGN,neutral
1406561.0,"The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering",2019-05-31 07:34:00-04:00,ZFGN,positive
1406562.0,56 Biggest Movers From Yesterday,2019-05-31 06:14:00-04:00,ZFGN,neutral
1406563.0,Mid-Afternoon Market Update: BOS Better Online Solutions Falls After Q1 Results; Organovo Holdings Shares Rise,2019-05-30 16:00:00-04:00,ZFGN,positive
1406564.0,44 Stocks Moving In Thursday's Mid-Day Session,2019-05-30 12:27:00-04:00,ZFGN,neutral
1406565.0,Mid-Day Market Update: Crude Oil Down 1.7%; Titan Machinery Shares Surge Following Upbeat Q1 Results,2019-05-30 12:02:00-04:00,ZFGN,negative
1406566.0,Micro-Cap Biotech Zafgen Plunges To Record Low: What You Need To Know,2019-05-30 10:44:00-04:00,ZFGN,negative
1406567.0,Mid-Morning Market Update: Markets Open Higher; Dollar General Tops Q1 Expectations,2019-05-30 10:11:00-04:00,ZFGN,positive
1406568.0,Zafgen shares are trading lower after the company announced it received FDA Type A meeting minutes related to the previously announced clinical Hold on its ZGN-1061.,2019-05-30 09:23:00-04:00,ZFGN,neutral
1406569.0,Zafgen Announces Receipt Of Type A Meeting Minutes From FDA Regarding Clinical Hold For ZGN-1061; Co. Is Also Exploring A Second IND For ZGN-1061 In A Population With A Higher Inmet Medical Need,2019-05-30 07:04:00-04:00,ZFGN,neutral
1406570.0,64 Biggest Movers From Yesterday,2019-05-30 05:08:00-04:00,ZFGN,neutral
1406571.0,Zafgen Q1 EPS $(0.35) Beats $(0.42) Estimate,2019-05-09 16:20:00-04:00,ZFGN,neutral
1406572.0,"Roth Capital Initiates Coverage On Zafgen, Inc. - Common Stock with Buy Rating",2019-04-26 08:52:00-04:00,ZFGN,neutral
1406573.0,"The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings",2019-04-25 07:58:00-04:00,ZFGN,neutral
1406574.0,"The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova",2019-04-24 08:09:00-04:00,ZFGN,neutral
1406575.0,"The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale",2019-04-23 08:08:00-04:00,ZFGN,positive
1406576.0,"The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs",2019-03-26 07:36:00-04:00,ZFGN,positive
1406577.0,"The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie",2019-03-13 07:27:00-04:00,ZFGN,negative
1406578.0,56 Biggest Movers From Yesterday,2019-03-13 06:04:00-04:00,ZFGN,neutral
1406579.0,Mid-Afternoon Market Update: Momo Rises On Upbeat Q4 Results; Valhi Shares Slide,2019-03-12 14:55:00-04:00,ZFGN,positive
1406580.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-03-12 14:06:00-04:00,ZFGN,neutral
1406581.0,Mid-Day Market Update: Stitch Fix Jumps Following Strong Q2 Results; Zafgen Shares Plummet,2019-03-12 12:22:00-04:00,ZFGN,positive
1406582.0,Mid-Morning Market Update: Markets Mixed; Dicks Sporting Goods Profit Tops Views,2019-03-12 10:17:00-04:00,ZFGN,positive
1406583.0,25 Stocks Moving In Tuesday's Pre-Market Session,2019-03-12 08:02:00-04:00,ZFGN,neutral
1406584.0,"The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug",2019-03-12 07:47:00-04:00,ZFGN,positive
1406585.0,A Peek Into The Markets: US Stock Futures Mostly Higher Ahead Of Consumer Price Index,2019-03-12 07:32:00-04:00,ZFGN,neutral
1406586.0,"7 Stocks To Watch For March 12, 2019",2019-03-12 04:30:00-04:00,ZFGN,neutral
1406587.0,"Zafgen shares are trading lower after the company announced it suspended its plans to file an IND application for ZGN-1258, based on a recent unexpected nonclinical finding in long-term toxicology studies.",2019-03-11 17:03:00-04:00,ZFGN,negative
1406588.0,5 Stocks Moving In Monday's After-Hours Session,2019-03-11 16:52:00-04:00,ZFGN,neutral
1406589.0,"Zafgen Shares Resume Trade, Down 24.4%",2019-03-11 16:36:00-04:00,ZFGN,positive
1406590.0,Zafgen Reports Chief Medical Officer Dennis Kim Resigned; Replacement Is Not Mentioned,2019-03-11 16:16:00-04:00,ZFGN,negative
1406591.0,Zafgen Inc Common Stock Shares To Resume Trade At 4:35 p.m. EDT,2019-03-11 16:12:00-04:00,ZFGN,positive
1406592.0,Zafgen Q4 EPS $(0.39) Beats $(0.44) Estimate,2019-03-11 16:10:00-04:00,ZFGN,neutral
1406593.0,Zafgen Suspends IND Filing Plans For Zgn-1258 Based On Nonclinical Finding In Long-Term Toxicology Studies,2019-03-11 16:10:00-04:00,ZFGN,neutral
1406594.0,Zafgen Shares Halted News Pending,2019-03-11 16:00:00-04:00,ZFGN,positive
1406595.0,"Earnings Scheduled For March 11, 2019",2019-03-11 04:17:00-04:00,ZFGN,neutral
1406596.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs",2019-03-10 14:32:00-04:00,ZFGN,neutral
1406597.0,72 Biggest Movers From Yesterday,2019-02-08 05:18:00-05:00,ZFGN,neutral
1406598.0,Zafgen shares are trading higher after Leerink Swann upgraded the company's stock from Market Perform to Outperform.,2019-02-07 12:31:00-05:00,ZFGN,positive
1406599.0,54 Stocks Moving In Thursday's Mid-Day Session,2019-02-07 12:28:00-05:00,ZFGN,neutral
1406600.0,"Benzinga's Top Upgrades, Downgrades For February 7, 2019",2019-02-07 09:05:00-05:00,ZFGN,positive
1406601.0,Leerink Swann Upgrades Zafgen to Outperform,2019-02-07 06:37:00-05:00,ZFGN,neutral
1406602.0,"The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive",2019-01-29 07:25:00-05:00,ZFGN,neutral
1406603.0,"Stocks Which Set New 52-Week Low Mon., Jan. 28, 2019",2019-01-28 15:33:00-05:00,ZFGN,negative
1406604.0,"The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug",2019-01-25 07:38:00-05:00,ZFGN,positive
1406605.0,"Stocks Which Set New 52-Week Low Yesterday, Jan. 24, 2019",2019-01-24 10:05:00-05:00,ZFGN,negative
1406606.0,"The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial",2019-01-24 07:45:00-05:00,ZFGN,negative
1406607.0,22 Stocks Moving In Thursday's Pre-Market Session,2019-01-17 07:58:00-05:00,ZFGN,neutral
1406608.0,"Zafgen Announces Results For Second Cohort Of Phase 2 Clinical Trial Of ZGN-1061; Data Showed Statistically Significant Reduction Of A1C, Supported Safety And Tolerability Profile",2019-01-17 07:09:00-05:00,ZFGN,positive
1406609.0,Zafgen shares are trading lower after after announcing the FDA placed clinical hold on its investigational new drug application for ZGN-1061.,2018-11-27 08:06:00-05:00,ZFGN,neutral
1406610.0,41 Biggest Movers From Yesterday,2018-11-27 05:08:00-05:00,ZFGN,neutral
1406611.0,Mid-Afternoon Market Update: Dow Up Over 300 Points; JinkoSolar Shares Rise After Q3 Results,2018-11-26 14:29:00-05:00,ZFGN,positive
1406612.0,33 Stocks Moving In Monday's Mid-Day Session,2018-11-26 12:45:00-05:00,ZFGN,neutral
1406613.0,Mid-Day Market Update: Crude Oil Up 3%; Zafgen Shares Plummet,2018-11-26 12:06:00-05:00,ZFGN,negative
1406614.0,Mid-Morning Market Update: Markets Open Higher; Diana Shipping Profit Tops Estimates,2018-11-26 10:35:00-05:00,ZFGN,positive
1406615.0,UPDATE: Piper Jaffray On Zafgen Clinical Hold: 'We believe the FDA is exercising additional caution following drug-related deaths for discontinued first-gen MetAP2 inhibitor beloranib',2018-11-26 09:45:00-05:00,ZFGN,negative
1406616.0,"Piper Jaffray Reiterates Overweight Rating, $18 Price Target On Zafgen With Shares Down 45% Following News Of A Clinical Hold",2018-11-26 09:44:00-05:00,ZFGN,negative
1406617.0,Zafgen shares are trading down 34.2% premarket after the FDA placed a clinical hold on its investigational new drug application for its first trial of diabetes drug ZGN-1061 due to safety concerns.,2018-11-26 08:58:00-05:00,ZFGN,positive
1406618.0,Zafgen Shares To Resume Trade At 7:30 a.m. EST,2018-11-26 07:26:00-05:00,ZFGN,positive
1406619.0,Zafgen Announces the FDA Has Placed a Clinical Hold on the Investigational New Drug Application for the First Trial of ZGN-1061,2018-11-26 07:01:00-05:00,ZFGN,neutral
1406620.0,"Zafgen Halted, News Pending",2018-11-26 06:58:00-05:00,ZFGN,neutral
1406621.0,Zafgen Filing Shows REgistration For $50M Common Stock Offering,2018-11-09 16:59:00-05:00,ZFGN,neutral
1406622.0,Zafgen Q3 EPS $(0.41) Beats $(0.48) Estimate,2018-11-07 17:28:00-05:00,ZFGN,neutral
1406623.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,ZFGN,negative
1406624.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,ZFGN,neutral
1406625.0,"Stocks Which Set New 52-Week High Yesterday, September 26th",2018-09-27 09:12:00-04:00,ZFGN,neutral
1406626.0,"Stocks Which Set New 52-Week High Yesterday, September 25th",2018-09-26 11:53:00-04:00,ZFGN,neutral
1406627.0,"The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial",2018-09-26 08:25:00-04:00,ZFGN,positive
1406628.0,"Stocks Which Set New 52-Week High Yesterday, September 24th",2018-09-25 09:06:00-04:00,ZFGN,neutral
1406629.0,"Stocks Which Set New 52-Week High Yesterday, September 20th",2018-09-21 08:16:00-04:00,ZFGN,neutral
1406630.0,Zafgen Q2 EPS $(0.57) Beats $(0.59) Estimate,2018-08-07 17:14:00-04:00,ZFGN,neutral
1406631.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,ZFGN,negative
1406632.0,"Benzinga's Top Upgrades, Downgrades For August 3, 2018",2018-08-03 09:41:00-04:00,ZFGN,positive
1406633.0,"Wedbush Initiates Coverage On Zafgen with Outperform Rating, Announces $14 Price Target",2018-08-03 09:17:00-04:00,ZFGN,neutral
1406634.0,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings",2018-08-03 07:52:00-04:00,ZFGN,neutral
1406635.0,"Zafgen Reports Pres, Chief Scientific Officer Thomas Hughes Resigned; Search For Successor Underway",2018-08-02 16:59:00-04:00,ZFGN,neutral
1406636.0,Stocks Which Set New 52-Week Highs Friday,2018-07-23 11:08:00-04:00,ZFGN,neutral
1406637.0,"Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index",2018-07-05 07:43:00-04:00,ZFGN,neutral
1406638.0,45 Biggest Movers From Tuesday,2018-07-05 04:40:00-04:00,ZFGN,neutral
1406639.0,34 Stocks Moving In Tuesday's Mid-Day Session,2018-07-03 12:30:00-04:00,ZFGN,neutral
1406640.0,"Benzinga's Top Upgrades, Downgrades For July 3, 2018",2018-07-03 09:00:00-04:00,ZFGN,positive
1406641.0,"PiperJaffray Initiates Coverage On Zafgen with Overweight Rating, Announces $18 Price Target",2018-07-03 08:09:00-04:00,ZFGN,negative
1406642.0,48 Biggest Movers From Yesterday,2018-06-29 04:06:00-04:00,ZFGN,neutral
1406643.0,"Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut",2018-06-28 08:26:00-04:00,ZFGN,positive
1406644.0,20 Stocks Moving In Thursday's Pre-Market Session,2018-06-28 08:13:00-04:00,ZFGN,neutral
1406645.0,Zafgen Prices 8M Share Offering at $.750/Share,2018-06-28 08:13:00-04:00,ZFGN,positive
1406646.0,Zafgen Prices 8M Share Offering At $7.50/Share,2018-06-28 08:03:00-04:00,ZFGN,positive
1406647.0,Hearing Zafgen To Offer Shares Of Common Stock In $7.50-$7.75/Share Range,2018-06-27 16:23:00-04:00,ZFGN,positive
1406648.0,"Zafgen Reports Offering Of Common Stock, No Size Disclosed",2018-06-27 16:02:00-04:00,ZFGN,negative
1406649.0,44 Biggest Movers From Yesterday,2018-06-26 04:50:00-04:00,ZFGN,neutral
1406650.0,Mid-Afternoon Market Update: NASDAQ Down Over 2.5%; Xerium Technologies Shares Spike Higher,2018-06-25 14:32:00-04:00,ZFGN,positive
1406651.0,Zafgen Shares Up 22.9% After Co. On Saturday Announced Positive Results From Phase 2 Proof-Of-Concept Trial Of ZGN-1061 In Patients With Difficult-To-Control Type 2 Diabetes,2018-06-25 14:23:00-04:00,ZFGN,positive
1406652.0,36 Stocks Moving In Monday's Mid-Day Session,2018-06-25 12:26:00-04:00,ZFGN,neutral
1406653.0,Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes at #ADA2018,2018-06-23 19:03:00-04:00,ZFGN,positive
1406654.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs",2018-06-17 16:16:00-04:00,ZFGN,neutral
1406655.0,Zafgen Q1 EPS $(0.58) Misses $(0.52) Estimate,2018-05-08 17:15:00-04:00,ZFGN,negative
1406656.0,38 Biggest Movers From Yesterday,2018-04-17 04:46:00-04:00,ZFGN,neutral
1406657.0,31 Stocks Moving In Monday's Mid-Day Session,2018-04-16 12:19:00-04:00,ZFGN,neutral
1406658.0,31 Stocks Moving In Wednesday's Mid-Day Session,2018-03-07 12:29:00-05:00,ZFGN,neutral
1406659.0,"Zafgen Shares Up 2.1%; Tuesday Co. Reported Q4 EPS $(0.48) vs $(0.52) Est., Expects To End 2018 With $40M+ In Cash and Cash Equivalents",2018-03-07 11:45:00-05:00,ZFGN,positive
1406660.0,35 Stocks Moving In Friday's Mid-Day Session,2018-02-02 12:22:00-05:00,ZFGN,neutral
1406661.0,46 Biggest Movers From Yesterday,2018-02-01 04:46:00-05:00,ZFGN,neutral
1406662.0,UPDATE: Zafgen Says 'Company returning to rare disorders with ZGN-1258; Prader-Willi syndrome expected as first indication',2018-01-05 07:06:00-05:00,ZFGN,neutral
1406663.0,Zafgen Reports 'ZGN-1061 Phase 2 trial fully enrolled with type 2 diabetes patients; topline data expected mid-year',2018-01-05 07:06:00-05:00,ZFGN,neutral
1406664.0,Zafgen Reports Q3 EPS $(0.46) vs $(0.58) Est.,2017-11-07 16:37:00-05:00,ZFGN,neutral
1406665.0,"Zafgen Names Jeffrey Hatfield CEO; Thomas Hughes Will Continue As Pres, Named Chief Scientific Officer",2017-10-10 07:00:00-04:00,ZFGN,neutral
1406666.0,Zafgen Initiates Phase 2 Trial For ZGN-1061,2017-09-12 16:07:00-04:00,ZFGN,neutral
1406667.0,S-3 From Zafgen Shows Registration For $150M Mixed Securities Shelf Offering,2017-08-09 16:38:00-04:00,ZFGN,positive
1406668.0,Zafgen Reports Q2 EPS $(0.49) vs $(0.52) Est.,2017-08-08 18:05:00-04:00,ZFGN,neutral
1406669.0,Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at #2017ADA,2017-06-11 11:45:00-04:00,ZFGN,neutral
1406670.0,Zafgen Reports Q1 EPS $(0.48) vs $(0.43) In Prior Year Period,2017-05-09 17:16:00-04:00,ZFGN,neutral
1406671.0,20 Biggest Mid-Day Gainers For Friday,2017-05-05 12:27:00-04:00,ZFGN,neutral
1406672.0,22 Stocks Moving In Friday's Pre-Market Session,2017-05-05 08:13:00-04:00,ZFGN,neutral
1406673.0,"Zafgen Shares Resumed, Stock Now Up 12.5%",2017-05-04 16:49:00-04:00,ZFGN,positive
1406674.0,Zafgen Shares to Resume Trade at 4:35 p.m. EDT,2017-05-04 16:26:00-04:00,ZFGN,positive
1406675.0,"Zafgen Issues Phase 1 Data for ZGN-1061: Showed Rapid Drug Absorption, Clearance In Line with Pre-Specified Criteria, was Well Tolerated, Safe, No Evidence of Prothrombotic Effects",2017-05-04 16:26:00-04:00,ZFGN,positive
1406676.0,Zafgen Shares Halted News Pending,2017-05-04 16:02:00-04:00,ZFGN,positive
1406677.0,Zafgen Reports Q4 EPS $(0.38) vs. $(0.50) Est.,2017-03-09 16:23:00-05:00,ZFGN,neutral
1406678.0,15 Stocks Moving In Monday's Pre-Market Session,2017-01-09 08:22:00-05:00,ZFGN,neutral
1406679.0,15 Biggest Mid-Day Gainers For Friday,2017-01-06 12:51:00-05:00,ZFGN,neutral
1406680.0,18 Stocks Moving In Friday's Pre-Market Session,2017-01-06 08:25:00-05:00,ZFGN,neutral
1406681.0,JMP Securities Upgrades Zafgen to Market Outperform,2017-01-06 06:24:00-05:00,ZFGN,positive
1406682.0,"10 Stocks That Rallied Four Days, Then Sold Off Yesterday",2016-12-08 05:15:00-05:00,ZFGN,neutral
1406683.0,Zafgen Reports Q3 EPS $(0.54) vs. Est $(0.61),2016-11-09 17:20:00-05:00,ZFGN,neutral
1406684.0,10 Stocks That Plummeted The Past Three Days On Increasing Volume,2016-11-07 07:11:00-05:00,ZFGN,neutral
1406685.0,Zafgen Begins Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of ZGN-1061,2016-09-20 07:00:00-04:00,ZFGN,neutral
1406686.0,Zafgen Spikes to High of $3.13 on Volume,2016-09-06 10:53:00-04:00,ZFGN,neutral
1406687.0,"CEO Hughes Buys 10,000 Shares of Zafgen @$3.00/Share -Form 4",2016-08-31 16:17:00-04:00,ZFGN,positive
1406688.0,Zafgen Reports Q2 EPS $(0.55) vs. Est. $(0.66),2016-08-04 17:27:00-04:00,ZFGN,neutral
1406689.0,"CFO Allen Buys 16,000 Shares of Zafgen @$3.12/Share -Form 4",2016-07-26 17:16:00-04:00,ZFGN,positive
1406690.0,Option Alert: ZFGN Jan17 2.5 Puts Sweep: 500 @  ASK  $0.40: 1548 traded vs 148 OI:  Earnings 8/9  $2.99 Ref,2016-07-21 13:54:00-04:00,ZFGN,positive
1406691.0,Mid-Afternoon Market Update: NASDAQ Up Over 1%; Cintas Shares Surge On Upbeat Earnings,2016-07-20 14:44:00-04:00,ZFGN,positive
1406692.0,10 Biggest Mid-Day Losers For Wednesday,2016-07-20 12:54:00-04:00,ZFGN,negative
1406693.0,Mid-Day Market Update: Microsoft Gains Following Earnings Beat; Zafgen Shares Slide,2016-07-20 12:19:00-04:00,ZFGN,positive
1406694.0,Stocks Hitting 52-Week Lows,2016-07-20 10:18:00-04:00,ZFGN,negative
1406695.0,Mid-Morning Market Update: Markets Open Higher; Morgan Stanley Beats Q2 Estimates,2016-07-20 09:51:00-04:00,ZFGN,neutral
1406696.0,FBR Capital Downgrades Zafgen to Market Perform,2016-07-20 09:35:00-04:00,ZFGN,neutral
1406697.0,15 Stocks Moving In Wednesday's Pre-Market Session,2016-07-20 08:21:00-04:00,ZFGN,neutral
1406698.0,Cowen & Company Downgrades Zafgen to Market Perform,2016-07-20 07:47:00-04:00,ZFGN,neutral
1406699.0,"Zafgen -45.33%	Premarket @$3.69; Co Announced Tuesday, Suspension Development of Obesity Drug Beloranib",2016-07-20 07:13:00-04:00,ZFGN,neutral
1406700.0,"After-Hours Losers: ZFGN Down 41.5%, EXPO 9.7%, IBKR 2.8%, DFS 2.6%, SRPT 2%, UAL 0.5%",2016-07-19 17:47:00-04:00,ZFGN,negative
1406701.0,"Zafgen Suspends Development Of Beloranib, Implementing Strategic Restructuring To Reduce Workforce By 34%; Will Result In Charge Of $4.8M",2016-07-19 16:09:00-04:00,ZFGN,neutral
1406702.0,Zafgen Announces New Data from the Phase 2b Clinical Trial Evaluating Beloranib in Severe Obesity Complicated by Type 2 Diabetes at the American Diabetes Association's 76th Scientific Sessions,2016-06-12 08:27:00-04:00,ZFGN,negative
1406703.0,"Zafgen Shares Pare Gains, Off Session High of $7.73 by ~$0.40; Stock Still Up ~4% for Session",2016-06-02 11:46:00-04:00,ZFGN,positive
1406704.0,"Zafgen Shares Spike ~$0.30 Over Last Few Mins, Now Up 4.5% for Session",2016-06-02 11:17:00-04:00,ZFGN,positive
1406705.0,Zafgen Reports Q1 EPS $(0.65) vs. Est. $(0.74),2016-05-10 17:06:00-04:00,ZFGN,neutral
1406706.0,"Zafgen Management Really Believes It Will Have Clinical Hold Removed; Decision Could Come In 4-6 Months, Analyst Says",2016-04-11 13:21:00-04:00,ZFGN,neutral
1406707.0,Mid-Morning Market Update: Markets Mostly Flat; Alaska Air To Acquire Virgin America For $57/Share,2016-04-04 10:12:00-04:00,ZFGN,neutral
1406708.0,10 Stocks Moving In Monday's Pre-Market Session,2016-04-04 08:20:00-04:00,ZFGN,neutral
1406710.0,Zafgen Shares Surge On Positive Phase 3 Trial,2016-04-04 08:06:00-04:00,ZFGN,positive
1406711.0,"Zafgen Announces Beloranib was Associated with Improvement in Total Cholesterol, LDL Cholesterol, Other Markers of Cardiometabolic Risk",2016-04-03 14:17:00-04:00,ZFGN,positive
1406712.0,Canaccord Genuity Downgrades Zafgen to Hold,2016-03-10 09:12:00-05:00,ZFGN,neutral
1406713.0,Zafgen Reports Q4 EPS $(0.85) vs. Est. $(0.80),2016-03-09 16:10:00-05:00,ZFGN,neutral
1406714.0,"Thromboembolic Risks Linger For Zafgen's Beloranib, Says SunTrust",2016-02-19 16:05:00-05:00,ZFGN,negative
1406715.0,Here's Why Zafgen Gained 20% Thursday Morning,2016-02-18 08:48:00-05:00,ZFGN,positive
1406716.0,10 Stocks Moving In Thursday's Pre-Market Session,2016-02-18 08:27:00-05:00,ZFGN,neutral
1406717.0,Zafgen +19.5% Premarket @$8.90; Co.'s Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Met Primary Efficacy Endpoint,2016-02-18 07:26:00-05:00,ZFGN,negative
1406718.0,"UPDATE: Zafgen Says Beloranib Showed Statistically, Clinically Significant Improvements in Body Weight, Glycemic Control Over Six Months of Random Treatment",2016-02-18 06:39:00-05:00,ZFGN,positive
1406719.0,Zafgen Reports Co.'s Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Hit Primary Efficacy Endpoint,2016-02-18 06:38:00-05:00,ZFGN,negative
1406720.0,Vetr Top Raters Downgrade Zafgen To 1.5-Star Stock,2016-02-16 15:36:00-05:00,ZFGN,positive
1406721.0,Mid-Day Market Update: Crude Oil Falls 5%; Tyco Shares Surge Following Johnson Controls Merger Agreement,2016-01-25 12:29:00-05:00,ZFGN,positive
1406722.0,Mid-Morning Market Update: Markets Open Lower; McDonald's Beats Q4 Estimates,2016-01-25 10:01:00-05:00,ZFGN,negative
1406723.0,"Kerrisdale Short Zafgen, Says Beloranib Has 'No Reasonable Chance' Of FDA Approval And Recent Bullishness Is 'Misplaced'",2016-01-25 09:36:00-05:00,ZFGN,positive
1406724.0,UPDATE: Kerrisdale Believes Zafgen Stock Worth Only $3/Share,2016-01-25 09:33:00-05:00,ZFGN,positive
1406725.0,"UPDATE: Kerrisdale On Zafgen Short: Recent Excitement About Beloranib Efficacy Is 'Misplaced,' Says Drug Leads To Weight Loss OF 4-5% But Increases Risk Of Death 4X",2016-01-25 09:33:00-05:00,ZFGN,negative
1406726.0,"Zafgen Shares Plummet On Open, Kerrisdale Capital Releases Negative Report; Trading At $7.56/Share",2016-01-25 09:31:00-05:00,ZFGN,negative
1406727.0,"Kerrisdale Capital Short Zafgen With $3 Price Target, Says Obesity Drug Has 'No Reasonable Chance' Of FDA Approval",2016-01-25 09:30:00-05:00,ZFGN,positive
1406728.0,Zafgen Doubles: What Do The Experts Think?,2016-01-21 11:51:00-05:00,ZFGN,neutral
1406729.0,Benzinga's Volume Movers,2016-01-21 10:13:00-05:00,ZFGN,neutral
1406730.0,Benzinga's Top Upgrades,2016-01-21 08:50:00-05:00,ZFGN,positive
1406731.0,10 Stocks Moving In Thursday's Pre-Market Session,2016-01-21 08:19:00-05:00,ZFGN,neutral
1406732.0,"Zafgen +20.62% Premarket @$20.11 Following Upgrades at RBC, FBR",2016-01-21 08:15:00-05:00,ZFGN,neutral
1406733.0,RBC Capital Upgrades Zafgen to Outperform,2016-01-21 06:29:00-05:00,ZFGN,neutral
1406734.0,FBR Capital Upgrades Zafgen to Outperform,2016-01-21 05:55:00-05:00,ZFGN,neutral
1406735.0,Zafgen +5.6% Premarket @$10.61; FBR Upgrades to Outperform With $20 PT,2016-01-21 05:47:00-05:00,ZFGN,neutral
1406736.0,Mid-Afternoon Market Update: Dow Falls Over 400 Points; Advanced Micro Devices Shares Drop After Disappointing Guidance,2016-01-20 14:48:00-05:00,ZFGN,negative
1406737.0,Zafgen Up 77% After Positive Results For Obesity Drug,2016-01-20 10:50:00-05:00,ZFGN,positive
1406738.0,Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Q4 Profit Drops,2016-01-20 09:55:00-05:00,ZFGN,positive
1406739.0,Why Zafgen Is Trading Higher By 40%,2016-01-20 08:45:00-05:00,ZFGN,neutral
1406740.0,10 Stocks Moving In Wednesday's Pre-Market Session,2016-01-20 08:24:00-05:00,ZFGN,neutral
1406741.0,UPDATE: Zafgen +80% Premarket @$10.10; Co Announces Phase 3 Obesity Drug Trial Achieves Co-Primary Efficacy Endpoint,2016-01-20 07:15:00-05:00,ZFGN,neutral
1406742.0,Zafgen +38% Premarket @$7.75; Co Announces Phase 3 Obesity Drug Trial Achieves Co-Primary Efficacy Endpoint,2016-01-20 06:32:00-05:00,ZFGN,neutral
1406743.0,Zafgen Announces Phase 3 Trial Achieves Co-Primary Efficacy Endpoint,2016-01-20 06:01:00-05:00,ZFGN,neutral
1406744.0,"James E. Flynn Reports 4.94% Stake In Zafgen Inc Zfgn.O As Of December 3, 2015 -",2015-12-14 13:12:00-05:00,ZFGN,neutral
1406745.0,Morning Market Losers,2015-12-03 09:59:00-05:00,ZFGN,negative
1406746.0,Benzinga's Top Downgrades,2015-12-03 09:21:00-05:00,ZFGN,positive
1406747.0,Benzinga's Top #PreMarket Losers,2015-12-03 08:18:00-05:00,ZFGN,negative
1406748.0,"Early Global News: American Express Expanding In Russia, Baidu To Merge Its Music Business, China Taking Big Steps To Open Market",2015-12-03 07:38:00-05:00,ZFGN,neutral
1406749.0,"SunTrust Robinson Humphrey Downgrades Zafgen to Neutral, Lowers PT to $7.00",2015-12-03 07:29:00-05:00,ZFGN,negative
1406750.0,Mid-Afternoon Market Update: Dow Slides 150 Points; G-III Apparel Shares Rise On Earnings Beat,2015-12-02 15:01:00-05:00,ZFGN,positive
1406751.0,Mid-Day Market Update: Crude Oil Drops Over 2.5%; On Deck Capital Shares Surge Following Partnership With JPMorgan,2015-12-02 12:23:00-05:00,ZFGN,negative
1406752.0,Stocks Hitting 52-Week Lows,2015-12-02 10:19:00-05:00,ZFGN,negative
1406753.0,Mid-Morning Market Update: Markets Edge Higher; SAIC Earnings Top Expectations,2015-12-02 10:06:00-05:00,ZFGN,positive
1406754.0,Morning Market Losers,2015-12-02 09:57:00-05:00,ZFGN,negative
1406755.0,Death Of Another Patient Causes Zafgen's Shares To Plunge,2015-12-02 09:51:00-05:00,ZFGN,negative
1406756.0,Benzinga's Top #PreMarket Losers,2015-12-02 08:21:00-05:00,ZFGN,negative
1406757.0,Zafgen -50% Premarket; Co Reported Patient Death in Clinical Update on Beloranib,2015-12-02 07:37:00-05:00,ZFGN,negative
1406758.0,Zafgen Offers Clinical Update on Beloranib: Co. Learned Patient Who Received Candidate as Part of OLE Portion Has Died,2015-12-02 06:32:00-05:00,ZFGN,negative
1406759.0,Zafgen Sells Off to Low on Volume,2015-11-30 12:38:00-05:00,ZFGN,negative
1406760.0,Zafgen Reports Q3 EPS $(0.73) vs. Est. $(0.79),2015-11-10 16:02:00-05:00,ZFGN,neutral
1406761.0,Morning Market Gainers,2015-10-22 09:45:00-04:00,ZFGN,neutral
1406762.0,Benzinga's Top #PreMarket Gainers,2015-10-22 08:12:00-04:00,ZFGN,positive
1406763.0,Zafgen Says Cause Of Death Of Patient Has Been Determined To Be Respiratory Failure Due To Pulmonary Embolism; Not Known If The Death Of The Patient Was Related To Treatment With Beloranib,2015-10-22 06:42:00-04:00,ZFGN,negative
1406764.0,"Zafgen Expects ZAF-311 to Remain Pivotal Clinical Trial; Says Expects To Report Top-Line Results From ZAF-311, ZAF-203 Clinical Trials In Q1 Of 2016",2015-10-22 06:38:00-04:00,ZFGN,neutral
1406765.0,Zafgen Gives Update on Beloranib,2015-10-22 06:36:00-04:00,ZFGN,neutral
1406766.0,"Zafgen Controversy Means Stock Is Worth $25 Now, Notes SunTrust",2015-10-19 14:40:00-04:00,ZFGN,positive
1406767.0,Benzinga's Volume Movers,2015-10-19 10:37:00-04:00,ZFGN,neutral
1406768.0,Morning Market Gainers,2015-10-19 09:39:00-04:00,ZFGN,neutral
1406769.0,Benzinga's Top #PreMarket Gainers,2015-10-19 08:17:00-04:00,ZFGN,positive
1406770.0,"Zafgen +6% Premarket; Suntrust Maintained Buy Rating, Lowering PT to $25 from $47",2015-10-19 06:33:00-04:00,ZFGN,negative
1406771.0,Mid-Afternoon Market Update: Crude Oil Rises 2%; Zafgen Shares Dip On Beloranib Partial Clinical Hold,2015-10-16 15:28:00-04:00,ZFGN,negative
1406772.0,Mid-Day Market Update: Youku Tudou Jumps Following Announcement of Proposal from Alibaba; Quanta Services Shares Slide,2015-10-16 12:22:00-04:00,ZFGN,positive
1406773.0,Mid-Morning Market Update: Markets Edge Higher; General Electric Profit Tops Expectations,2015-10-16 10:08:00-04:00,ZFGN,positive
1406774.0,Morning Market Losers,2015-10-16 09:51:00-04:00,ZFGN,negative
1406775.0,Benzinga's Top #PreMarket Losers,2015-10-16 08:24:00-04:00,ZFGN,negative
1406776.0,Zafgen Falls 25% Premarket on Beloranib Partial Clinical Hold,2015-10-16 06:33:00-04:00,ZFGN,neutral
1406777.0,"UPDATE: Zafgen CEO Says 'Patient safety is our top priority, and we will work closely with the FDA to implement these measures to support the further development of beloranib'",2015-10-16 06:32:00-04:00,ZFGN,positive
1406778.0,Zafgen Reports Partial Clinical Hold Related to Beloranib Trials,2015-10-16 06:31:00-04:00,ZFGN,neutral
1406779.0,Benzinga's Volume Movers,2015-10-15 10:46:00-04:00,ZFGN,neutral
1406780.0,RBC Spoke With Zafgen Management After The Beloranib Patient Death; Here Are The Takeaways,2015-10-14 15:32:00-04:00,ZFGN,negative
1406781.0,"Zafgen Shares Spiking To HOD, Up ~30% To $20.67",2015-10-14 14:18:00-04:00,ZFGN,positive
1406782.0,"Hearing Zafgen Defended At RBC Capital, Chatter RBC Saying Worst Case Scenario Of A Clinical Hold Is Avoided",2015-10-14 13:20:00-04:00,ZFGN,negative
1406783.0,Zafgen Now +12% as Shares Reverse Course After Hitting Low of $10.90 on Statement Regarding Patient Death,2015-10-14 13:16:00-04:00,ZFGN,negative
1406784.0,"Shares of Zafgen Resume Following Breaker, Now Down ~20%",2015-10-14 12:35:00-04:00,ZFGN,positive
1406785.0,UPDATE: Zafgen Shares Halted Down ~11%,2015-10-14 12:32:00-04:00,ZFGN,positive
1406786.0,Zafgen Shares Halted on Circuit Breaker Following Resumption,2015-10-14 12:31:00-04:00,ZFGN,positive
1406787.0,Zafgen Trading Down $14/Share On Phase 3 Patient Death,2015-10-14 12:30:00-04:00,ZFGN,negative
1406788.0,Reminder Zafgen Shares To Resume Trading At 12:30pm EDT,2015-10-14 12:28:00-04:00,ZFGN,positive
1406789.0,Zafgen To Resume Trade At 12:30pm ET,2015-10-14 12:05:00-04:00,ZFGN,neutral
1406790.0,UPDATE: Zafgen Says Cause Of Death Of Patient In Phase 3 bestPWS Study of Beloranib Remains Unknown At This Time,2015-10-14 12:02:00-04:00,ZFGN,negative
1406791.0,UPDATE: Zafgen Says Patient Death Occurred In Company  Phase 3 best PWS Study,2015-10-14 12:01:00-04:00,ZFGN,positive
1406792.0,Zafgen Issues Statement,2015-10-14 12:00:00-04:00,ZFGN,neutral
1406793.0,Zafgen Trading Halted-News Pending,2015-10-14 11:48:00-04:00,ZFGN,neutral
1406794.0,Shares of Zafgen Bounce Off Session Lows Following Earlier Mid-Day Note from SunTrust Defending Stock Amid Massive Decline This Week,2015-10-14 11:40:00-04:00,ZFGN,positive
1406795.0,Morning Market Gainers,2015-10-14 09:42:00-04:00,ZFGN,neutral
1406796.0,Benzinga's Top #PreMarket Gainers,2015-10-14 08:12:00-04:00,ZFGN,positive
1406797.0,Zafgen +5% Premarket,2015-10-14 07:34:00-04:00,ZFGN,neutral
1406798.0,Shares of Zafgen Trading Down 32+%; Bloomberg Earlier Reported Co. Cancelled an Event with RBC Amid a Scheduling Conflict,2015-10-12 15:05:00-04:00,ZFGN,negative
1406799.0,"Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now",2015-10-06 14:08:00-04:00,ZFGN,neutral
1406800.0,US Stock Futures Jump; ADP Report In Focus,2015-09-30 07:42:00-04:00,ZFGN,neutral
1406801.0,"Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Craniopharyngioma",2015-09-30 07:02:00-04:00,ZFGN,positive
1406802.0,Zafgen Announces Transition of Board of Directors,2015-09-28 07:05:00-04:00,ZFGN,neutral
1406803.0,Zafgen Completes Enrollment of Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes,2015-09-09 07:01:00-04:00,ZFGN,negative
1406804.0,Zafgen Reports Q2 EPS $(0.66) vs. Est. $(0.71),2015-08-11 16:12:00-04:00,ZFGN,neutral
1406805.0,"Zafgen Initiated At Buy, $47 Target By SunTrust",2015-06-17 11:06:00-04:00,ZFGN,neutral
1406806.0,Benzinga's Top Initiations,2015-06-17 09:29:00-04:00,ZFGN,positive
1406807.0,"Sunturst RObinson Humphrey Initiates Coverage on Zafgen at Buy, Announces $47.00 PT",2015-06-17 06:54:00-04:00,ZFGN,neutral
1406808.0,Zafgen Completes Enrollment of US Phase 3 Trial of Beloranib in Prader-Willi Syndrome,2015-05-28 07:05:00-04:00,ZFGN,neutral
1406809.0,Zafgen Reports Q1 Loss $0.53 Vs Exp Loss $0.65,2015-05-12 16:23:00-04:00,ZFGN,negative
1406810.0,afgen Presents Positive Safety and Efficacy Data From Phase 2 Trial of Beloranib in Severe Obesity and Proof of Concept Trial in Prader-Willi Syndrome,2015-05-08 10:00:00-04:00,ZFGN,positive
1406811.0,"Zafgen to Make Oral, Poster Presentations at 22nd European Congress on Obesity",2015-05-07 05:02:00-04:00,ZFGN,neutral
1406812.0,Benzinga's Top Initiations,2015-04-21 09:36:00-04:00,ZFGN,positive
1406813.0,FBR Capital Initiates Zafgen With Outperform,2015-04-21 08:29:00-04:00,ZFGN,neutral
1406814.0,"FBR Capital Initiates Coverage on Zafgen at Outperform, Announces $60.00 PT",2015-04-21 06:07:00-04:00,ZFGN,neutral
1406815.0,Stocks Hitting 52-Week Highs,2015-03-20 10:06:00-04:00,ZFGN,neutral
1406816.0,Zafgen Reports Q4 Loss of $0.48/Share vs Loss of $0.84/Share Est.,2015-03-19 16:01:00-04:00,ZFGN,negative
1406817.0,"Earnings Scheduled For March 19, 2015",2015-03-19 05:09:00-04:00,ZFGN,neutral
1406818.0,Zafgen Announces Positive Data  from Phase 2 Trial of Beloranib in Hypothalamic Injury Associated Obesity at ENDO 2015,2015-03-07 16:08:00-05:00,ZFGN,positive
1406819.0,Benzinga's Volume Movers,2015-01-23 10:34:00-05:00,ZFGN,neutral
1406820.0,Zafgen Prices ~3.942M Share Offering @$35.00/Share,2015-01-23 04:34:00-05:00,ZFGN,positive
1406821.0,5 Biotech Secondaries Traders Are Watching,2015-01-21 13:32:00-05:00,ZFGN,neutral
1406822.0,Zafgen Announces 2.8M Share Proposed Public Offering of Common Stock,2015-01-20 16:02:00-05:00,ZFGN,positive
1406823.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3,2015-01-13 10:58:00-05:00,ZFGN,neutral
1406824.0,Zafgen Files for Up to 2.5M Share Offering,2015-01-12 06:14:00-05:00,ZFGN,positive
1406825.0,"Zafgen Announces Positive Results From Phase 2 Study, Primary Endpoint Met",2015-01-07 07:03:00-05:00,ZFGN,positive
1406826.0,Will Zafgen Continue To Surge Higher?,2014-12-24 15:06:00-05:00,ZFGN,neutral
1406827.0,Zafgen Reports Q3 EPS of $(0.65) vs $(0.87) Est,2014-11-11 16:18:00-05:00,ZFGN,neutral
1406828.0,US Stock Futures Edge Lower Ahead Of ADP Report,2014-10-01 07:38:00-04:00,ZFGN,negative
1406829.0,"Zafgen Reports Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome, Trial Will Trigger $6.7M Milestone Payment Primarily to CKD",2014-10-01 07:00:00-04:00,ZFGN,neutral
1406830.0,Zafgen Initiates Phase 3 Trial of Beloranib in Prader-Willi Syndrome ,2014-10-01 06:57:00-04:00,ZFGN,neutral
1406831.0,Zafgen Completes Enrollment Of Phase 2a Trial Of Beloranib In Hypothalamic Injury-Associated Obesity,2014-09-25 07:01:00-04:00,ZFGN,neutral
1406832.0,Zafgen Reports Q2 EPS of $(2.96) vs $(3.04) Est,2014-08-13 16:36:00-04:00,ZFGN,neutral
1406833.0,Canaccord Genuity Initiates Coverage on Zafgen at Buy,2014-08-13 08:11:00-04:00,ZFGN,neutral
1406834.0,Benzinga's Top Initiations,2014-07-29 09:14:00-04:00,ZFGN,positive
1406835.0,JMP Securities Initiates Zafgen At Market Outperform,2014-07-29 07:47:00-04:00,ZFGN,positive
1406836.0,"JMP Securities Initiates Coverage on Zafgen at Market Outperform, Announces $31.00 PT",2014-07-29 06:25:00-04:00,ZFGN,positive
1406837.0,"Leerink Swann Initiates Coverage on Zafgen at Outperform, Announces $35.00 PT",2014-07-24 06:42:00-04:00,ZFGN,neutral
1406838.0,"Cowen & Company Initiates Coverage on Zafgen at Outperform, Announces $45.00 PT",2014-07-14 09:25:00-04:00,ZFGN,neutral
1406839.0,Zafgen Announces Orphan Drug Designation with EU For Beloranib,2014-07-10 07:01:00-04:00,ZFGN,neutral
1406840.0,Zafgen Appoints New Member of Board of Directors; Frank Thomas ,2014-06-26 17:01:00-04:00,ZFGN,neutral
1406841.0,IPO Lookout: IPOs Up Double Digits On The Week ,2014-06-20 16:09:00-04:00,ZFGN,neutral
1406842.0,"Adam Feuerstein Likes Zafgen, Bluebird Bio",2014-06-20 08:33:00-04:00,ZFGN,positive
1406843.0,"Zafgen Opens at $20/Share, Priced at $16",2014-06-19 11:16:00-04:00,ZFGN,neutral
1406844.0,Waiting on 5 IPOs This Morning,2014-06-19 08:35:00-04:00,ZFGN,neutral
1406845.0,"Zafgen Prices IPO at $16/Share, 6M Shares Offered",2014-06-18 17:12:00-04:00,ZFGN,positive
1406846.0,IPO Lookout: 14 IPOs For The Week Of June 16,2014-06-16 09:25:00-04:00,ZFGN,neutral
